# Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe

## TL;DR

This study confirms the effectiveness of sacituzumab govitecan in treating metastatic triple-negative breast cancer in real-world settings.

## Contribution

The study provides real-world evidence of sacituzumab govitecan's effectiveness in a multinational cohort of metastatic triple-negative breast cancer patients.

## Key findings

- Median progression-free survival was 4.4 months and median overall survival was 11.3 months.
- The overall response rate was 30.7% with neutropenia and anemia being the most frequent adverse events.

## Abstract

Sacituzumab govitecan (SG), an antibody–drug conjugate targeting TROP-2, demonstrated superior efficacy over standard chemotherapy in heavily pretreated metastatic triple-negative breast cancer (mTNBC) in the ASCENT trial. However, real-world data remain limited. This study evaluated the effectiveness and safety of SG in an unselected multinational cohort of patients with mTNBC.

This retrospective analysis included 303 women who initiated SG treatment between August 2021 and April 2025 across 18 oncology centers in Poland, the Czech Republic and Slovakia, within the Central European Breast Cancer Collaboration (CEBCC-102). Primary endpoints were median progression-free survival (mPFS) and overall survival (mOS). Secondary objectives included response pattern, safety and identification of factors influencing outcomes. Adverse events (AEs) were graded using Common Terminology Criteria for AE, version 5.0, and treatment response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

The median follow-up was 8.8 months (IQR 4.5-14.4). The mPFS was 4.4 months, and mOS was 11.3 months. The overall response rate was 30.7%. The most frequent AEs were hematologic: neutropenia (69.0%) and anemia (39.6%). In multivariate Cox analyses, poor ECOG performance status and liver metastases were independently associated with worse outcomes. Diarrhea and hypersensitivity reactions showed favorable prognostic associations.

In this largest real-world cohort, the clinical benefit of SG observed in the ASCENT trial was confirmed under routine practice conditions. Poor performance status and liver metastases predicted inferior outcomes, while certain treatment-related AEs warrant further investigation.